Topical calcipotriol plus betamethasone dipropionate for the treatment of plaque psoriasis: a drug evaluation

References

• Vakirlis E. Calcipotriol/betamethasone dipropionate in the treatment of psoriasis vulgaris. Ther Clin Risk Manag. 2008;03/01(4):141–148.
   Google Scholar
• Stern RS, Nijsten T, Feldman SR, et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Invest Dermatol Symp Proc. 2004;9(2):136–139.
   PubMed Web of Science ®Google Scholar
• McCormack PL. Calcipotriol/betamethasone dipropionate.Drugs. 2011 [2011 04 01];71(6):709–730.
   PubMed Web of Science ®Google Scholar
• Vanderpuye-Orgle J, Zhao Y, Lu J, et al. Evaluating the economic burden of psoriasis in the United States. J Am Acad Dermatol. 2015 [2015 06 01];72(6):961–67.e5.
   PubMed Web of Science ®Google Scholar
• Douglas WS, Poulin Y, Decroix J, et al. A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venereol. 2002;82(2):131–135.
   PubMed Web of Science ®Google Scholar
• Alexis AF, Blackcloud P. Psoriasis in skin of color: epidemiology, genetics, clinical presentation, and treatment nuances. J Clin Aesthet Dermatol. 2014;7(11):16–24.
   PubMedGoogle Scholar
• Sarkar R, Chugh S, Bansal S. General measures and quality of life issues in psoriasis. Indian Dermatol Online J. 2016;7(6):481–488. 2016 Nov-Dec.
   PubMedGoogle Scholar
• Nguyen CM, Beroukhim K, Danesh MJ, et al. The psychosocial impact of acne, vitiligo, and psoriasis: a review. Clin Cosmet Investig Dermatol. 2016;9:383–392. [ 11/2/pubmed 11/2/medline11/2/entrez].
   PubMed Web of Science ®Google Scholar
• Psomadakis CE, New HG. Emerging topical therapies for psoriasis and atopic dermatitis. J Clin Aesthet Dermatol. 2019;12(12):28–34.
   PubMedGoogle Scholar
• Stein Gold LF. Topical therapies for psoriasis: improving management strategies and patient adherence. Semin Cutan Med Surg. 2016 Mar;35(2Suppl 2):S36-44;quiz S45;quiz S45.
   Google Scholar
• Armstrong AW, Koning JW, Rowse S, et al. Under-treatment of patients with moderate to severe psoriasis in the United States: analysis of medication usage with health plan data. Dermatol Ther (Heidelb). 2017;7(1):97–109.
   PubMed Web of Science ®Google Scholar
• Fenton C, Plosker GL. Calcipotriol/betamethasone dipropionate. Am J Clin Dermatol. 2004;5(6):463–478.
   PubMed Web of Science ®Google Scholar
• Kragballe K, Van De Kerkhof P. Pooled safety analysis of calcipotriol plus betamethasone dipropionate gel for the treatment of psoriasis on the body and scalp. J Eur Acad Dermatol Venereol. 2014;28:10–21.
   PubMed Web of Science ®Google Scholar
• Elmets CA, Korman NJ, Prater EF, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol. 2021;84(2):432-470.
   PubMed Web of Science ®Google Scholar
• Warren RB, Hansen JB, Reich K, et al. Complete clearance and psoriasis area and severity index response for brodalumab and ustekinumab in AMAGINE-2 and −3.J Eur Acad Dermatol Venereol. 2021 [2021 02 01];35(2):450–457.
   PubMed Web of Science ®Google Scholar
• Bagel J, Nelson E, Zapata J, et al. Adjunctive use of calcipotriene/betamethasone dipropionate foam in a real-world setting curtails the cost of biologics without reducing efficacy in psoriasis. Dermatol Ther (Heidelb). 2020;10(6):1383–1396.
   PubMed Web of Science ®Google Scholar
• Takahashi H, Katayama H, Uwajima Y, et al. Patient satisfaction and efficacy of calcipotriol plus betamethasone dipropionate gel in plaque psoriasis patients with poor adherence. J Dermatol. 2020;47(11):1249–1256.
   PubMed Web of Science ®Google Scholar
• Balak DMW, Carrascosa J-M, Gregoriou S, et al. Cost per PASI-75 responder of calcipotriol plus betamethasone dipropionate cutaneous foam versus nonbiologic systemic therapies for the treatment of plaque psoriasis in seven European countries. J Dermatological Treat 2020 1–8 DOI: 10.1080/09546634.2019.1707754
   PubMed Web of Science ®Google Scholar
• Duvetorp A, Levin L, Engerstedt Mattsson E, et al. Analysis of calcipotriol/betamethasone dipropionate aerosol foam versus ointment for the topical treatment of psoriasis Vulgaris in Sweden. Acta Derm Venereol. 2019 Apr 1;99(4):393–399.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Goffe B, Rice G, et al. The challenge of managing psoriasis: unmet medical needs and stakeholder perspectives. Am Health Drug Benefits. 2016;9(9):504–513.
   PubMed Web of Science ®Google Scholar
• Stein Gold L, Alonso-Llamazares J, Lacour J-P, et al., PSO-LONG: design of a novel, 12-month clinical trial of topical, proactive maintenance with twice-weekly Cal/BD Foam in Psoriasis. Adv Ther. 37(11): 4730–4753. 2020.
   PubMed Web of Science ®Google Scholar
• Uva L, Miguel D, Pinheiro C, et al. Mechanisms of action of topical corticosteroids in psoriasis. Int J Endocrinol. 2012;2012:1–16.
   Web of Science ®Google Scholar
• James WD, Elston D, Treat JR, et al. Andrews’ diseases of the skin: clinical dermatology. thirteenth ed. Elsevier;2019.
   Google Scholar
• Zhang P, Wu MX. A clinical review of phototherapy for psoriasis. Lasers Med Sci. 2018;33(1):173–180.
   PubMed Web of Science ®Google Scholar
• Zeichner JA. Use of topical coal tar foam for the treatment of psoriasis in difficult-to-treat areas. J Clin Aesthet Dermatol. 2010;3(9):37–40.
   PubMedGoogle Scholar
• Kin KC, Hill D, Feldman SR. Calcipotriene and betamethasone dipropionate for the topical treatment of plaque psoriasis.Expert Rev Clin Pharmacol. 2016 [2016 06 02];9(6):789–797.
   PubMed Web of Science ®Google Scholar
• Dyring-Andersen B, Bonefeld CM, Bzorek M, et al. The vitamin D analogue calcipotriol reduces the frequency of CD8+ IL-17+ T cells in psoriasis lesions. Scand J Immunol. 2015 Jul;82(1):84–91.
   PubMed Web of Science ®Google Scholar
• Haussler MR, Whitfield GK, Kaneko I, et al. Molecular mechanisms of vitamin D action. Calcif Tissue Int. 2013 Feb;92(2):77–98.
   PubMed Web of Science ®Google Scholar
• Uva L, Miguel D, Pinheiro C, et al. Mechanisms of action of topical corticosteroids in psoriasis. Int J Endocrinol. 2012;2012: 561018–18.
   PubMed Web of Science ®Google Scholar
• Simonsen L, Høy G, Didriksen E, et al. Development of a new formulation combining calcipotriol and betamethasone dipropionate in an ointment vehicle.Drug Dev Ind Pharm. 2004 [2004 01 01];30(10):1095–1102.
   PubMed Web of Science ®Google Scholar
• Lequang JA. Updates in psoriasis management: based on selected presentations from Maui Derm 2020. J Clin Aesthet Dermatol. 2020 January 25 –29,;13(7 Suppl):S1–S17. Maui, Hawaii.
   PubMedGoogle Scholar
• Wynzora (calcipotriene and betamethasone dipropionate) cream. [ cited 2020 Sept 5]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213422s000lbl.pdf
   Google Scholar
• Kim ES, Frampton JE. Calcipotriol/betamethasone dipropionate foam: a review in plaque psoriasis. Drugs. 2016;76(15):1485–1492.
   PubMed Web of Science ®Google Scholar
• TACLONEX® (calcipotriene and betamethasone dipropionate) Topical Suspension, 0.005%/0.064%. 2006 [ cited 2020 Sept 6]. Availablefrom: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022185s012lbl.pdf
   Google Scholar
• DOVOBET Gel. 2013 [cited 2020 Sept 6]. Available from: http://www.leo-pharma.ca/Files/Filer/LEO_local_downloads/LEO-Pharma.ca/Dovobet%20gel%20PM%20(2.0)%2008-Feb-2013.pdf
   Google Scholar
• Patel NU, Felix K, Reimer D, et al. Calcipotriene/betamethasone dipropionate for the treatment of psoriasis vulgaris: an evidence-based review. Clin Cosmet Investig Dermatol. 2017;10:385–391.
   PubMed Web of Science ®Google Scholar
• Rigopoulos D, Baran R, Chiheb S, et al. Recommendations for the definition, evaluation, and treatment of nail psoriasis in adult patients with no or mild skin psoriasis: a dermatologist and nail expert group consensus. J Am Acad Dermatol. 2019;81(1):228–240.
   PubMed Web of Science ®Google Scholar
• Rigopoulos D, Gregoriou S, Daniel Iii CR, et al. Treatment of nail psoriasis with a two-compound formulation of calcipotriol plus betamethasone dipropionate ointment. Dermatology. 2009;218(4):338–341.
   PubMed Web of Science ®Google Scholar
• Gregoriou S, Sidiropoulou P, Tsimpidakis A, et al. Treatment of nail psoriasis with calcipotriol/betamethasone dipropionate foam versus pulse dye laser: an unblinded, intra-patient, left-to-right prospective study. J Eur Acad Dermatol Venereol. 2020 Sep;34(9):e519–e20.
   PubMed Web of Science ®Google Scholar
• Taclonex (calcipotriene and betamethasone dipropionate) Ointment. Prescribing Information. cited 2020 Sept 4; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021852s015lbl.pdf
   Google Scholar
• Seyger M, Abramovits W, Liljedahl M, et al. Safety and efficacy of fixed-dose combination calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) cutaneous foam in adolescent patients (aged 12 to <17 years) with plaque psoriasis: results of a phase II, open-label trial. J Eur Acad Dermatol Venereol. 2020;34(9):2026–2034.
   PubMed Web of Science ®Google Scholar
• Traulsen J. Bioavailability of betamethasone dipropionate when combined with calcipotriol. Int J Dermatol. 2004 Aug;43(8):611–617.
   PubMed Web of Science ®Google Scholar
• Queille-Roussel C, Bang B, Clonier F, et al. Enhanced vasoconstrictor potency of the fixed combination calcipotriol plus betamethasone dipropionate in an innovative aerosol foam formulation vs. other corticosteroid psoriasis treatments. J Eur Acad Dermatol Venereol. 2016 Nov;30(11):1951–1956.
   PubMed Web of Science ®Google Scholar
• Queille-Roussel C, Nielsen J, Lacour JP. Vasoconstrictor potency of fixed-dose combination calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) cutaneous foam versus other topical corticosteroids used to treat psoriasis vulgaris. J Dermatolog Treat. 2019 Sep;30(6):529–533.
   PubMed Web of Science ®Google Scholar
• Fleming C, Ganslandt C, Leese GP. Short- and long-term safety assessment of a two-compound ointment containing calcipotriene/betamethasone dipropionate (Taclonex/Daivobet/Dovobet ointment): hypothalamic-pituitary-adrenal axis function in patients with psoriasis vulgaris. J Drugs Dermatol. 2010 Aug;9(8):969–974.
   PubMed Web of Science ®Google Scholar
• Kragballe K, Austad J, Barnes L, et al. A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgaris. Br J Dermatol. 2006 Jun;154(6):1155–1160.
   PubMed Web of Science ®Google Scholar
• Norsgaard H, Kurdykowski S, Descargues P, et al. Calcipotriol counteracts betamethasone-induced decrease in extracellular matrix components related to skin atrophy. Arch Dermatol Res. 2014 Oct;306(8):719–729.
   PubMed Web of Science ®Google Scholar
• Satake K, Amano T, Okamoto T. Low systemic exposure and calcemic effect of calcipotriol/betamethasone ointment in rats with imiquimod-induced psoriasis-like dermatitis. Eur J Pharmacol May 5. 2018;826:31–38.
   PubMed Web of Science ®Google Scholar
• DOVONEX®(calcipotriene) Cream, 0.005%.
   Google Scholar
• Kaufmann R, Bibby AJ, Bissonnette R, et al. A new calcipotriol/betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris. Dermatology. 2002;205(4):389–393.
   PubMed Web of Science ®Google Scholar
• Guenther L, Cambazard F, Van De Kerkhof PCM, et al. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol. 2002;147(2):316–323.
   Google Scholar
• Papp KA, Guenther L, Boyden B, et al. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol. 2003 Jan;48(1):48–54.
   PubMed Web of Science ®Google Scholar
• Ortonne JP, Kaufmann R, Lecha M, et al. Efficacy of treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol for the treatment of psoriasis vulgaris: a randomised, double-blind trial. Dermatology. 2004;209(4):308–313.
   PubMed Web of Science ®Google Scholar
• Kragballe K, Noerrelund KL, Lui H, et al. Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris. Br J Dermatol. 2004 Jun;150(6):1167–1173.
   PubMed Web of Science ®Google Scholar
• Langley RG, Gupta A, Papp K, et al. Calcipotriol plus betamethasone dipropionate gel compared with tacalcitol ointment and the gel vehicle alone in patients with psoriasis vulgaris: a randomized, controlled clinical trial. Dermatology. 2011;222(2):148–156.
   PubMed Web of Science ®Google Scholar
• Menter A, Gold LS, Bukhalo M, et al. Calcipotriene plus betamethasone dipropionate topical suspension for the treatment of mild to moderate psoriasis vulgaris on the body: a randomized, double-blind, vehicle-controlled trial. J Drugs Dermatol. 2013 Jan;12(1):92–98.
   PubMed Web of Science ®Google Scholar
• Lind M, Nielsen KT, Schefe LH, et al. Supersaturation of calcipotriene and betamethasone dipropionate in a novel aerosol foam formulation for topical treatment of psoriasis provides enhanced bioavailability of the active ingredients. Dermatol Ther (Heidelb). 2016 Sep;6(3):413–425 .
   PubMed Web of Science ®Google Scholar
• Koo J, Tyring S, Werschler W, et al. Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris - a randomized phase II study. J Dermatolog Treat. 2015;10/07(27):1–8.
   Google Scholar
• Lebwohl M, Tyring S, Bukhalo M, et al. Fixed combination aerosol foam calcipotriene 0.005% (cal) plus betamethasone dipropionate 0.064% (BD) is more efficacious than Cal or BD aerosol foam alone for psoriasis vulgaris: a randomized, double-blind, multicenter, three-arm, phase 2 study. J Clin Aesthet Dermatol. 2016 Feb;9(2):34–41.
   PubMedGoogle Scholar
• Leonardi C, Bagel J, Yamauchi P, et al. Efficacy and safety of calcipotriene plus betamethasone dipropionate aerosol foam in patients with psoriasis vulgaris–a randomized phase III study (PSO-FAST). J Drugs Dermatol. 2015 Dec;14(12):1468–1477.
   PubMed Web of Science ®Google Scholar
• Paul C, Stein Gold L, Cambazard F, et al. Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO-ABLE study. J Eur Acad Dermatol Venereol. 2017;31(1):119–126.
   PubMed Web of Science ®Google Scholar
• LEO 90100 twice weekly maintenance regimen for psoriasis vulgaris. [ cited 2020 Sept 10]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT02899962?term=lebwohl&draw=2&rank=9
   Google Scholar
• A clinical trial evaluating efficacy and safety of MC2-01 cream. [Internet]. U.S. National Library of Medicine. 2017. Available from: https://clinicaltrials.gov/ct2/show/results/NCT03308799?term=03308799&draw=2&rank=1
   Google Scholar
• Dattola A, Silvestri M, Bennardo L, et al. A novel vehicle for the treatment of psoriasis. Dermatol Ther. 2019;12(1):33.
   Google Scholar
• Gerdes S, Krakor M, Anger T, et al. Non-interventional, multicentre study on the efficacy and tolerability of a new calcipotriol/betamethasone aerosol foam (Enstilar®) in patients with plaque psoriasis under daily practice conditions. Dermatology. 2017;233(6):425–434.
   PubMed Web of Science ®Google Scholar
• Wu JJ, Veverka KA, Lu M, et al. Real-world experience of calcipotriene and betamethasone dipropionate foam 0.005%/0.064% in the treatment of adults with psoriasis in the United States. J Dermatolog Treat. 2019 Aug;30(5):454–460.
   PubMed Web of Science ®Google Scholar
• Guenther LC. Fixed-dose combination therapy for psoriasis. Am J Clin Dermatol. 2004;5(2):71–77.
   PubMed Web of Science ®Google Scholar
• Silver S, Tuppal R, Gupta AK, et al. Effect of calcipotriene plus betamethasone dipropionate topical suspension on the hypothalamic-pituitary-adrenal axis and calcium homeostasis in subjects with extensive psoriasis vulgaris: an open, non-controlled, 8-week trial. J Drugs Dermatol. 2013 Aug;12(8):882–887.
   PubMed Web of Science ®Google Scholar
• Taraska V, Tuppal R, Olesen M, et al. Foam formulation of calcipotriol and betamethasone has no impact on hpa axis and calcium homeostasis in patients with extensive psoriasis Vulgaris. J Cutan Med Surg. 2016;20(1):44–51.
   PubMed Web of Science ®Google Scholar
• Queille-Roussel C, Rosen M, Clonier F, et al. Efficacy and safety of calcipotriol plus betamethasone dipropionate aerosol foam compared with betamethasone 17-valerate-medicated plaster for the treatment of psoriasis. Clin Drug Investig. 2017 Apr;37(4):355–361.
   PubMed Web of Science ®Google Scholar